Patents by Inventor David Albert DRIVER

David Albert DRIVER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRANSFERRIN RECEPTOR BINDING PROTEINS AND CONJUGATES
    Publication number: 20240059784
    Abstract: Provided herein are proteins comprising one monovalent human TfR binding domain (“human TfR binding proteins”), proteins comprising one monovalent mouse TfR binding domain (“mouse TfR binding proteins”), conjugates comprising such human or mouse TfR binding proteins, e.g., human TfR binding proteins-dsRNA conjugates, pharmaceutical compositions comprising human TfR binding proteins or conjugates, and methods of treating CNS diseases (e.g., neurodegenerative disease such as neurodegenerative synucleinopathy or tauopathy) using human TfR binding proteins or conjugates.
    Type: Application
    Filed: August 7, 2023
    Publication date: February 22, 2024
    Inventors: Riazul Alam, Alberto Alvarado, Forest Hoyt Andrews, Nicholas Alan Babb, Deepa Balasubramaniam, Guillermo S. Cortez, Johnny Eugene Croy, David Albert Driver, Ross Edward Fellows, Daniel Girard, Lacie Chauvigne-Hines, Feng Liu, Hiroaki Tani, Isabel C. Gonzalez Valcarcel, Scott Alan Lawrence, Nalini Hosahalli Kulkarni, Jeremy S York
  • COMPOUNDS AND METHODS TARGETING HUMAN TAU
    Publication number: 20220146535
    Abstract: The present invention provides compounds and methods targeting human tau, particularly human tau phosphorylated at threonine 217 and isoforms of tau expressed only in the CNS, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of neurodegenerative diseases such as AD, PSP and FTD.
    Type: Application
    Filed: November 24, 2021
    Publication date: May 12, 2022
    Inventors: Xiyun CHAI, Jinbiao CHEN, Jeffrey L. Dage, David Albert Driver, Steven Fisher Hinton, Robert William Siegel, II, Peter Edward Vaillancourt
  • Fibroblast growth factor 21 variant, composition , and uses thereof
    Patent number: 9422353
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: August 23, 2016
    Assignee: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • FIBROBLAST GROWTH FACTOR 21 VARIANTS
    Publication number: 20150141327
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) variants, pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such variants.
    Type: Application
    Filed: June 5, 2013
    Publication date: May 21, 2015
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • Fibroblast growth factor 21 proteins
    Patent number: 8927492
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: January 6, 2015
    Assignee: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • Fibroblast growth factor 21 variants
    Patent number: 8883726
    Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: November 11, 2014
    Assignee: Eli Lilly and Company
    Inventors: Craig Duane Dickinson, David Albert Driver, Ryan James Darling, Malgorzata Donata Gonciarz, Radmila Micanovic
  • FIBROBLAST GROWTH FACTOR 21 PROTEINS
    Publication number: 20140228282
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.
    Type: Application
    Filed: April 23, 2014
    Publication date: August 14, 2014
    Applicant: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • Fibroblast growth factor 21 proteins
    Patent number: 8741841
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: June 3, 2014
    Assignee: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • FIBROBLAST GROWTH FACTOR 21 PROTEINS
    Publication number: 20130330336
    Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.
    Type: Application
    Filed: June 5, 2013
    Publication date: December 12, 2013
    Applicant: Eli Lilly and Company
    Inventors: Ryan James Darling, Craig Duane Dickinson, David Albert Driver, Malgorzata Donata Gonciarz
  • FIBROBLAST GROWTH FACTOR 21 VARIANTS
    Publication number: 20130324460
    Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.
    Type: Application
    Filed: August 13, 2013
    Publication date: December 5, 2013
    Applicant: Eli Lilly and Company
    Inventors: Craig Duane DICKINSON, David Albert DRIVER, Ryan James DARLING, Malgorzata Donata GONCIARZ, Radmila MICANOVIC
  • Fibroblast growth factor 21 variants having improved pharmacological potency and/or improved pharmaceutical stability
    Patent number: 8541369
    Abstract: This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21), pharmaceutical compositions comprising FGF21 variants, and methods for treating type 2 diabetes, obesity, dyslipidemia, or metabolic syndrome, or any combination thereof, using such variants.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: September 24, 2013
    Assignee: Eli Lilly and Company
    Inventors: Craig Duane Dickinson, David Albert Driver, Ryan James Darling, Maigorzata Donata Gonciarz, Radmila Micanovic